Physician profile
Devin R Willis
NPI 1295175057
$1,016.07
in general payments reported to CMS, 2019-2025
19 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.89 · 2020: $239 · 2021: $425 · 2022: $145 · 2023: $40.10 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $211.20 | 2021-2023 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $137.65 | 2019-2022 | |
| Novo Nordisk INC | $128.35 | 2020-2022 | |
| Abiomed | $110.48 | 2025 | |
| Merck Sharp & Dohme LLC | $63.01 | 2020-2021 | |
| Amgen INC. | $57.55 | 2019-2021 | |
| Eisai INC. | $45.42 | 2021 | |
| Lilly USA, LLC | $44.71 | 2021-2022 | |
| Pfizer INC. | $31.13 | 2019-2021 | |
| Genentech USA, INC. | $23.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.83 | 2023 | Jardiance, Glyxambi |
| Biohaven Pharmaceuticals, INC. | $22.53 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.74 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.34 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.83 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.42 | 2022 | |
| Adlon Therapeutics L.P. | $16.73 | 2020 | |
| Amarin Pharma, INC. | $12.79 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.